title: [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
abstract: Autoimmune glomerulopathies are an important cause of chronic kidney disease. Conventional treatments based on steroids, antiproliferative and cytotoxic agents are efficacious, but highly toxic. Because of their central role in the pathogenesis of autoimmunity, B cells have become an attractive therapeutic target. Rituximab is a monoclonal antibody directed against CD20 expressed on the surface of B cells, inducing profound depletion of B cells in the peripheral blood. In spite of encouraging results regarding the off-label use of Rituximab in membranous nephropathy, systemic lupus erythematosus and small vessel vasculitis, controlled, long-term data, and data with specific renal endpoints are currently lacking.
authors: Service de néphrologie et consultation d'hypertension, Département de médecine, CHUV, 1011 Lausanne. laila-yasmin.mani@chuv.ch
authors: Laila-Yasmin
authors: LY
authors: Mani
authors: Bruno
authors: B
authors: Vogt
authors: Michel
authors: M
authors: Burnier
authors: Déla
authors: D
authors: Golshayan